SOCRA CCRP 2026 Questions & Answers | Latest
Study Guide
1. If a sponsor fails to notify IRBs and investigators within the required time
frame after FDA approval is withdrawn, what potential consequences could
arise?
Legal and ethical repercussions for the sponsor and potential harm
to trial participants.
A requirement to submit additional documentation to the FDA.
Increased funding for the trial due to extended timelines.
No consequences as the trial can continue without FDA approval.
2. How long must companies wait upon submitting an IND to the FDA for review
before initiating the next step of the process?
30 days
20 days
5 days
10 days
3. If a clinical trial's data is found to be inaccurately recorded, what potential
consequences could arise?
The trial results may be deemed invalid, leading to regulatory
penalties and loss of credibility.
The trial can proceed without any issues.
Participants will automatically receive compensation.
The data can be corrected without any repercussions.
,4. What is the maximum time frame for the FDA to issue a written explanation
following a clinical hold on an IND?
30 days
60 days
90 days
15 days
5. An IRB/IEC is required to retain records for at least how many years after
completion of a trial?
2 years
5 years
10 years
3 years
6. Describe the significance of CFR 21 Part 312 in the context of clinical trials.
CFR 21 Part 312 specifies the responsibilities of Institutional Review
Boards.
CFR 21 Part 312 provides guidelines for ethical considerations in
clinical trials.
CFR 21 Part 312 outlines the regulations for submitting
Investigational New Drug applications, which are essential for the
approval of new drugs for clinical testing.
CFR 21 Part 312 details the reporting requirements for adverse events.
,7. Which of the following is the adverse event reporting program sponsored by
the US Food and Drug Administration (FDA) that allows for voluntarily
reporting of observed or suspected adverse events?
MedWatch
Sentinel Event Reporting System (SERS)
Patient Safety Organizations (PSOs)
Vaccine Adverse Event Reporting System (VAERS)
8. The research protocol must be approved by a designated Institutional
Review Board:
There is no designated time for approval.
After the first participant is randomized.
By the last participant has completed the last follow up visit.
Before the research study can begin.
9. What is the duration for which an IND remains on clinical hold before it is
inactivated?
90 days
30 days
60 days
120 days
10. What is the name of the significant document published by the National
Commission for the Protection of Human Subjects?
The Declaration of Helsinki
The Belmont Report
, The Common Rule
The Nuremberg Code
11. An SAE is a medical event associated with
Death
Life threatening event
Hospitalization or increased hospitalization stay
All of the above
12. If a pharmaceutical company is preparing to conduct a clinical trial for a new
drug, which regulation must they comply with regarding the submission of
their application?
CFR 21 Part 312
CFR 21 Part 56
CFR 21 Part 314
CFR 21 Part 50
13. If a new clinical trial is being conducted in multiple countries, how would the
guidelines set by the ICH influence the trial's design and implementation?
The guidelines would allow the trial to bypass local regulations.
The guidelines would only apply to the country where the trial is
initiated.
The guidelines would ensure that the trial adheres to ethical
standards and regulatory requirements across all participating
countries.
The guidelines would focus on maximizing profit for the sponsors.
Study Guide
1. If a sponsor fails to notify IRBs and investigators within the required time
frame after FDA approval is withdrawn, what potential consequences could
arise?
Legal and ethical repercussions for the sponsor and potential harm
to trial participants.
A requirement to submit additional documentation to the FDA.
Increased funding for the trial due to extended timelines.
No consequences as the trial can continue without FDA approval.
2. How long must companies wait upon submitting an IND to the FDA for review
before initiating the next step of the process?
30 days
20 days
5 days
10 days
3. If a clinical trial's data is found to be inaccurately recorded, what potential
consequences could arise?
The trial results may be deemed invalid, leading to regulatory
penalties and loss of credibility.
The trial can proceed without any issues.
Participants will automatically receive compensation.
The data can be corrected without any repercussions.
,4. What is the maximum time frame for the FDA to issue a written explanation
following a clinical hold on an IND?
30 days
60 days
90 days
15 days
5. An IRB/IEC is required to retain records for at least how many years after
completion of a trial?
2 years
5 years
10 years
3 years
6. Describe the significance of CFR 21 Part 312 in the context of clinical trials.
CFR 21 Part 312 specifies the responsibilities of Institutional Review
Boards.
CFR 21 Part 312 provides guidelines for ethical considerations in
clinical trials.
CFR 21 Part 312 outlines the regulations for submitting
Investigational New Drug applications, which are essential for the
approval of new drugs for clinical testing.
CFR 21 Part 312 details the reporting requirements for adverse events.
,7. Which of the following is the adverse event reporting program sponsored by
the US Food and Drug Administration (FDA) that allows for voluntarily
reporting of observed or suspected adverse events?
MedWatch
Sentinel Event Reporting System (SERS)
Patient Safety Organizations (PSOs)
Vaccine Adverse Event Reporting System (VAERS)
8. The research protocol must be approved by a designated Institutional
Review Board:
There is no designated time for approval.
After the first participant is randomized.
By the last participant has completed the last follow up visit.
Before the research study can begin.
9. What is the duration for which an IND remains on clinical hold before it is
inactivated?
90 days
30 days
60 days
120 days
10. What is the name of the significant document published by the National
Commission for the Protection of Human Subjects?
The Declaration of Helsinki
The Belmont Report
, The Common Rule
The Nuremberg Code
11. An SAE is a medical event associated with
Death
Life threatening event
Hospitalization or increased hospitalization stay
All of the above
12. If a pharmaceutical company is preparing to conduct a clinical trial for a new
drug, which regulation must they comply with regarding the submission of
their application?
CFR 21 Part 312
CFR 21 Part 56
CFR 21 Part 314
CFR 21 Part 50
13. If a new clinical trial is being conducted in multiple countries, how would the
guidelines set by the ICH influence the trial's design and implementation?
The guidelines would allow the trial to bypass local regulations.
The guidelines would only apply to the country where the trial is
initiated.
The guidelines would ensure that the trial adheres to ethical
standards and regulatory requirements across all participating
countries.
The guidelines would focus on maximizing profit for the sponsors.
